STADA directly supplies MOVAPO® (apomorphine hydrochloride) and Ropivacaine ReadyfusOR in Australia.
At STADA Australia, we launched our specialty products, focused on the treatment of Parkinson’s disease, in Australia and New Zealand in 2016 and in August 2017, we expanded our portfolio to include Pain Management.
We work closely with Britannia Pharmaceuticals and BioQ Pharma to bring innovative therapies and the latest advancements to Australia and New Zealand.
STADA directly supplies MOVAPO® (apomorphine hydrochloride) and Ropivacaine ReadyfusOR in Australia. To learn more, please browse the following resources:
- MOVAPO Consumer Medicine Information
- MOVAPO Pre-Filled Syringe (PFS) Product Information
- MOVAPO Ampoule Product Information
- MOVAPO Pen Product Information
- MOVAPO Pen Consumer Medicine Information
- Ropivacaine ReadyfusOR Consumer Medicine Information
- Ropivacaine ReadyfusOR Product Information
Research and development
We invest in research and development to deliver innovative therapies that address the unmet needs of patients and their carers.
For all enquiries, please phone 1800 791 660 or email medinfo(at)stada.com.au